LSL Pharma Group announced a non brokered private placement financing of Units for the minimum of 6,250,000 units and maximum of 8,750,000 at an issue price of CAD 0.40 per unit for the minimum gross proceeds of CAD 2,500,000 and maximum of CAD 3,500,000 on March 7, 2024. Each unit will consists of one class A common share and one common share purchase warrant. Each Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 36 months following the closing of the Financing.

the Corporation may pay finders? fees of up to 5% of the gross proceeds raised from investors introduced to the Corporation by a finder, payable in cash; and finders? warrants of up to 5% of the number of Units issued to investors introduced to the Corporation by a finder.

Each Finder?s Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 18 months following the closing of the Financing. Each issued Unit, Common Share, Warrant, Warrant Share, Finder?s Warrant and Common Share issued upon the exercise of the Finder?s Warrant will be subject to a four month hold period under the applicable securities laws. The Financing and the Units for Debts are subject to the regulatory approvals, including the TSX Venture Exchange.